![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Under the in-licensing pact, Dr Reddy's USA will commercialise the Cyclophosphamide injection, an alkylating drug indicated for treatment of malignant lymphomas, for the US market.
Lead Product(s): Cyclophosphamide
Therapeutic Area: Oncology Product Name: Cyclophosphamide-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\\\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 12, 2024